Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Compass Therapeutics ( (CMPX) ) has provided an announcement.
On April 27, 2026, Compass Therapeutics reported full secondary endpoint data from its COMPANION-002 randomized Phase 2/3 trial of tovecimig plus paclitaxel versus paclitaxel alone in 168 patients with second-line biliary tract cancer. The combination delivered a statistically significant median progression-free survival of 4.7 months versus 2.6 months, and previously disclosed data showed an overall response rate of 17.1% versus 5.3%, reinforcing the drug’s potential in a population with no approved second-line standard of care.
Overall survival did not reach statistical significance in the intent-to-treat analysis because 54% of control patients crossed over to receive tovecimig, but those crossover patients achieved a median overall survival of 12.8 months compared with 6.1 months for non-crossover controls. With 85% of trial participants ultimately receiving tovecimig and a pooled median overall survival of 8.9 months, together with a manageable safety profile, the results position Compass to pursue regulatory discussions and underscore the candidate’s promise to reshape treatment expectations in advanced biliary tract cancer.
The most recent analyst rating on (CMPX) stock is a Buy with a $13.00 price target. To see the full list of analyst forecasts on Compass Therapeutics stock, see the CMPX Stock Forecast page.
Spark’s Take on CMPX Stock
According to Spark, TipRanks’ AI Analyst, CMPX is a Neutral.
The score is primarily shaped by weak operating fundamentals (minimal revenue, ongoing losses, and cash burn) partially offset by a strong balance sheet and a favorable corporate update indicating cash runway into 2028 and advancing pipeline milestones. Technical indicators remain soft, and valuation is difficult to support due to negative earnings and no dividend.
To see Spark’s full report on CMPX stock, click here.
More about Compass Therapeutics
Compass Therapeutics, Inc. is a Boston-based, clinical-stage, oncology-focused biopharmaceutical company listed on Nasdaq under the ticker CMPX. The company develops proprietary antibody-based therapeutics, including the DLL4 x VEGF-A bispecific antibody tovecimig, targeting difficult-to-treat cancers such as unresectable advanced, metastatic or recurrent biliary tract cancer in patients lacking actionable mutations.
Average Trading Volume: 2,354,304
Technical Sentiment Signal: Buy
Current Market Cap: $905.8M
See more data about CMPX stock on TipRanks’ Stock Analysis page.